MAP1LC3A and melanoma: In addition, Barceló and colleagues showed that both Vemurafenib-resistant BRAFV600E-mutant melanoma cells and biopsies from human melanoma relapsing under BRAFi expressed higher levels of the Cav3.1 isoform and the LC3 protein compared with their parental Vemurafenib-sensitive cell line or pre-treatment melanoma tumors, respectively (Table 1; Figure 1A and Figure 2).